Home > Publications Database > Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-β 1-40: A Correlational Study in Healthy Adults. > print

001     164202
005     20240320110017.0
024 7 _ |a 10.3233/JAD-210286
|2 doi
024 7 _ |a pmid:34250938
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
024 7 _ |a altmetric:109249654
|2 altmetric
037 _ _ |a DZNE-2022-00858
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zebhauser, Paul Theo
|b 0
245 _ _ |a Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-β 1-40: A Correlational Study in Healthy Adults.
260 _ _ |a Amsterdam
|c 2021
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710928772_2065
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Tau proteins are established biomarkers of neuroaxonal damage in a wide range of neurodegenerative conditions. Although measurement of total-Tau in the cerebrospinal fluid is widely used in research and clinical settings, the relationship between age and total-Tau in the cerebrospinal fluid is yet to be fully understood. While past studies reported a correlation between age and total-Tau in the cerebrospinal fluid of healthy adults, in clinical practice the same cut-off value is used independently of patient's age.To further explore the relationship between age and total-Tau and to disentangle neurodegenerative from drainage-dependent effects.We analyzed cerebrospinal fluid samples of 76 carefully selected cognitively healthy adults and included amyloid-β 1-40 as a potential marker of drainage from the brain's interstitial system.We found a significant correlation of total-Tau and age, which was no longer present when correcting total-Tau for amyloid-β 1-40 concentrations. These findings were replicated under varied inclusion criteria.Results call into question the association of age and total-Tau in the cerebrospinal fluid. Furthermore, they suggest diagnostic utility of amyloid-β 1-40 as a possible proxy for drainage-mechanisms into the cerebrospinal fluid when interpreting biomarker concentrations for neurodegenerative diseases.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a amyloid-beta 1–40
|2 Other
650 _ 7 |a tau proteins
|2 Other
650 _ 7 |a total-Tau
|2 Other
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Peptide Fragments
|2 NLM Chemicals
650 _ 7 |a amyloid beta-protein (1-40)
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 2 |a Age Factors
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Healthy Volunteers: statistics & numerical data
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Models, Statistical
|2 MeSH
650 _ 2 |a Peptide Fragments: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
700 1 _ |a Berthele, Achim
|b 1
700 1 _ |a Franz, Marie-Sophie
|b 2
700 1 _ |a Goldhardt, Oliver
|b 3
700 1 _ |a Diehl-Schmid, Janine
|0 P:(DE-2719)2811585
|b 4
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 5
|u dzne
700 1 _ |a Ortner, Marion
|b 6
700 1 _ |a Grimmer, Timo
|b 7
773 _ _ |a 10.3233/JAD-210286
|g Vol. 83, no. 1, p. 155 - 162
|0 PERI:(DE-600)2070772-1
|n 1
|p 155 - 162
|t Journal of Alzheimer's disease
|v 83
|y 2021
|x 1387-2877
856 4 _ |u https://pub.dzne.de/record/164202/files/DZNE-2022-00858_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/164202/files/DZNE-2022-00858_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:164202
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)2811585
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811122
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21